Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials

ConclusionThe therapeutic benefit of additional substances is less distinct in patients withRAS mutated as compared toRAS wildtype metastatic colorectal cancer, especially with regard to OS.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research